mFlusiva

The U.S. Food and Drug Administration (FDA) has granted approval for Moderna's trivalent flu vaccine, designated as mRNA-1010 and marketed under the name mFLUSIVA, for use in individuals aged 50 years and older.

Read on Ars Technica (opens in a new tab)

The U.S. Food and Drug Administration (FDA) has granted approval for mFlusiva, a novel influenza vaccine developed by Moderna, marking the first use of mRNA technology in a flu shot for adults aged 50 and older.

Read on The Guardian World (opens in a new tab)

Read on Ars Technica (opens in a new tab)